| Document |
Document Title |
|
WO/2024/065042A1 |
Provided are novel sulfur-containing lipids and nanoparticles containing such lipids and a cargo molecule, such as a nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for...
|
|
WO/2024/067560A1 |
Disclosed in the present invention are a sulfonamide compound and the medical use thereof as a STING inhibitor, specifically, a compound as represented by formula (I) or a pharmaceutically acceptable salt or ester or solvate thereof, whi...
|
|
WO/2024/051975A1 |
The present invention relates to a compound of formula (I) as defined herein. The present invention further relates to a mixture comprising or consisting of a compound of formula (la) and a compound of formula (lb) as defined herein, whe...
|
|
WO/2024/050725A1 |
The application discloses methods useful for the synthesis of certain 2, 3, 5, 6-alkyl-1, 4-benzoquinone compounds, including 2, 3, 5-trimethyl-6-nonylcyclohexa-2, 5-diene-1, 4-dione, and synthetic intermediates for the production thereof.
|
|
WO/2024/054871A1 |
The application discloses methods useful for the synthesis of certain 2,3,5,6-alkyl-1,4-benzoquinone compounds, including 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione, and synthetic intermediates for the production thereof.
|
|
WO/2024/044813A1 |
The present invention relates to novel fluoroallylamine sulfone derivatives that are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for the treatment of a variety of indications, e.g., fibrosis, cancer an...
|
|
WO/2024/047227A1 |
The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical c...
|
|
WO/2024/043334A1 |
The present invention addresses the problem of providing a compound and pharmaceutical composition that possesses inhibitory activity against the drug efflux pumps of drug-resistant bacteria and, when used in combination with another dru...
|
|
WO/2024/040995A1 |
The present application relates to a synthesis method for an N-methyl-3-substituted methyl-4-pyrazolecarboxamide derivative and N-methyl-3-substituted methyl-4-pyrazolecarboxylic acid, the method comprising the following steps: S1: synth...
|
|
WO/2024/042084A1 |
The present invention relates to a process for separating a mixture comprising lactide(s) and glycolide comprising the steps of: a) providing a mixture comprising lactide(s) and glycolide, wherein said mixture is provided in the molten s...
|
|
WO/2024/026568A1 |
Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compound...
|
|
WO/2024/024607A1 |
The present invention provides: a resin modifier that is used for a polycarbonate resin or a polyester carbonate resin; a resin using the resin modifier; and a use application of the resin. The present invention also provides: a cyclic d...
|
|
WO/2024/019560A1 |
The present invention provides a butadiene preparation method comprising a step for preparing butadiene by pyrolyzing a polyester, containing a repeating unit derived from 1,4-butanediol, or a polymer blend containing the polyester.
|
|
WO/2024/011415A1 |
Disclosed in the present invention is a method for preparing an o-iodophenyl compound, wherein an iodobenzene compound and an amide compound as raw materials are reacted in the presence of sodium hydride or n-butyllithium and a solvent t...
|
|
WO/2023/234687A1 |
The present invention provides a method for preparing an acylic acid and/or glycolide, comprising a step of pyrolyzing a hydroxyalkanoate copolymer in the presence of a catalyst containing tin.
|
|
WO/2023/213922A1 |
The present invention primarily relates to compounds of formula (I) as defined herein. It also relates to fragrance substance mixtures as defined herein and methods for producing the same and to perfumed products as defined herein and me...
|
|
WO/2023/208121A1 |
A method of preparing a methoxy poly(ethylene glycol)-b-poly(L-lactide) (mPEG-PLLA) block copolymer is disclosed. During preparation of lactide, a mixture of antimony trioxide and phosphoric acid is used as a catalyst; at the same time, ...
|
|
WO/2023/173717A1 |
The present invention relates to a preparation method for an intermediate compound acting as a posaconazole synthetic drug, and an intermediate compound prepared thereby. The preparation method for a compound of formula (I) provided by t...
|
|
WO/2023/019244A9 |
Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intoler...
|
|
WO/2023/146244A1 |
The present disclosure provides a benzodioxane scaffold compound having AIMP2-DX2 inhibitory activity or a pharmaceutically acceptable salt thereof. The present disclosure also provides a composition comprising such a compound or a pharm...
|
|
WO/2023/131667A1 |
Embodiments of the invention are directed to cooling compounds and cooling compositions having a unique cooling perception, as well as various edible, potable, and/or cosmetic products containing one or more cooling compounds having a ge...
|
|
WO/2023/118833A1 |
1. In one aspect, a process for the preparation of vilanterol ((R)-4-(2-((6-(2-((2,6- dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hy
droxymethyl)phenol; Compound VI) or a pharmaceutically acceptable salt thereof, comprises ...
|
|
WO/2023/113086A1 |
The present invention relates to: a salt compound comprising a negative ion having a specific structure represented by chemical formula 1, and a positive ion represented by chemical formula 2; a quencher including the salt compound; and ...
|
|
WO/2023/110394A1 |
The present invention is directed to a process for C-H insertion by the gem-hydrogenation of an internal alkyne.
|
|
WO/2023/107877A1 |
Glycerol acetal sulfate and sulfonates, which may be used in consumer products to provide surfactant properties.
|
|
WO/2023/097690A1 |
A method for preparing a β-nitro or azido alcohol by means of high-selectivity asymmetric catalytic carbonyl reduction. The route of the method is as follows: wherein R1, R2, R3, R4 and R5 are independently selected from any one of H, h...
|
|
WO/2023/097696A1 |
Disclosed is a method for synthesizing (1R)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-nitroethanol
. The route of the method is as follows: The method is used for synthesizing (1R)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-nitroethanol...
|
|
WO/2023/094654A1 |
The present invention relates to polyol-derived compounds and processes preparing the same.
|
|
WO/2023/097341A2 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein T, R1, R2, R3, R4, R5, R6, R7, W and V are as defined in the disclosure. Also disclosed are compositions containing the...
|
|
WO/2023/096111A1 |
The present application relates to a novel quinizarine derivative, wherein the quinizarine derivative has a bromodomain extra-terminal (BET) protein inhibition ability, and thus can be used in a pharmaceutical composition for preventing ...
|
|
WO/2023/083293A1 |
Provided in the present invention is a variety of pharmaceutically acceptable salts of eliglustat, comprising a napadisylate, oxalate, glutarate, mucate and various crystal forms thereof. Further provided are a pharmaceutical composition...
|
|
WO/2023/078909A1 |
The present invention relates to compounds of formula (I), a delivery system based on photoresponsive cyclic acetal or ketal compounds capable of liberating in a controlled manner active volatile carbonyl compounds into the surrounding u...
|
|
WO/2023/071865A1 |
The present invention belongs to the technical field of biodegradable materials. Disclosed are a method and a system for continuously preparing lactide by step control. The method comprises: (1) reacting a lactic acid oligomer and a depo...
|
|
WO/2023/066357A1 |
The present disclosure relates to fused cyclic compounds, preparation methods therefor, and medical uses thereof. Specifically, the present disclosure relates to the fused cyclic compound represented by general formula (I), a preparation...
|
|
WO/2023/036948A1 |
The invention pertains to a process for purifying meso-lactide which has a free acid content of at least 30 meq/kg comprising at least one step of subjecting a feed comprising at least 75 wt.% meso-lactide to solvent crystallisation foll...
|
|
WO/2023/029979A1 |
Provided is a method for preparing (S,Z)-3-(2-(4-((3,4-dichlorobenzyl)oxy)phenyl)-2,3-dihydrobe
nzo[b][1,4]dioxin-6-yl)-2-hydroxyacrylic acid and (S)-3-((S)-2-(4-((3,4-dichlorobenzyl)oxy)phenyl)-2,3-dihydro
benzo[b][1,4]dioxin-6-yl)-2-((...
|
|
WO/2023/027118A1 |
This resist composition generates an acid when being exposed to light and changes the solubility with respect to a developer through the action of the acid. The resist composition contains a compound including a cation (C0) represented b...
|
|
WO/2023/017136A1 |
A process of producing lactide from lactic acid comprises the steps of: a) feeding lactic acid, a hydrocarbon solvent and at least one catalyst into a reactor of a reactor system so as to form a reaction mixture in the reactor, b) reacti...
|
|
WO/2023/006580A1 |
The instant invention relates to thionolactone compounds useful as comonomers to introduce weak bonds for polymer degradation or functionalization. The invention is also directed to processes for the preparation of said compounds, notabl...
|
|
WO/2023/000135A1 |
Provided are new process and intermediates for preparing onapristone.
|
|
WO/2023/283523A1 |
The present disclosure generally relates to 2,3-dihydrobenzo[b][1,4]dioxin-6-yl containing compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclos...
|
|
WO/2022/263619A1 |
The present invention relates to a vinyl keto ester and intermediates of its synthesis, wherein the vinyl moiety of the vinyl hydroxy ester and of the intermediates is partly or fully deuterated. Furthermore, the present invention relate...
|
|
WO/2022/262712A1 |
Disclosed is a method for synthesizing glycolide, which is obtained by using methyl glycolate as a raw material and by means of the following two steps of reaction: (I) (II), wherein ROH is a 18-30 carbon linear or branched alcohol, acid...
|
|
WO/2022/258792A1 |
The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever...
|
|
WO/2022/260430A1 |
The present invention provides an isolation method enabling lactide racemate to be isolated in a high yield and with high efficiency without concern for side reactions even if L-lactide percentage is low.
|
|
WO/2022/255037A1 |
To provide a novel amino compound useful as an epoxy resin curing agent, a method for producing the same, etc., disclosed is an amino compound represented by formula (1) that has a quaternary carbon at the β-position of an amino group. ...
|
|
WO/2022/244715A1 |
Provided is a method for producing a 1,4-dioxane derivative represented by formula (2) and/or formula (10), including reacting water, an inorganic base, and fluoroalkene oxide represented by formula (1). Provided is a method for producin...
|
|
WO/2022/218914A1 |
The present invention refers to a process for preparing carbonyl-containing compounds of formula (Ia), (Ib) or (Ic) from Bisphenol A-based Polycarbonate and appropriate nucleophiles in the presence of imidazole or a derivative thereof as...
|
|
WO/2022/196178A1 |
To realize a method for producing glycolide that improves productivity of glycolide and suppresses generation of by-products. A method for producing glycolide that includes a first step for preparing a depolymerization reaction solution ...
|
|
WO/2022/183111A1 |
Described herein are compositions and methods for treating P. falciparum malaria by specifically activating apoptosis in cells that express PfGARP without activating apoptosis in subject host cells or parasite cells that do not express P...
|
